Quantcast

Latest Lapatinib Stories

2008-09-08 09:00:08

Cytokinetics, Incorporated (NASDAQ: CYTK) announced that data from its ongoing Phase I/II clinical trial of ispinesib were presented in a poster at the 2008 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium held on September 5-7, 2008 in Washington, DC. A poster entitled, "A Phase I-II Trial of Ispinesib, a Kinesin Spindle Protein (KSP) Inhibitor, Dosed Every Two Weeks in Patients (pts) with Locally Advanced (LA) or Metastatic Breast Cancer (MBC) Previously Untreated...

2008-09-06 21:00:04

Many breast cancers are made worse by the hormone oestrogen and women take drugs known as aromatase inhibitors to reduce the oestrogen in their body and restrict the cancer's progress. But eventually the tumour becomes resistant to this treatment and starts to grow.Now American researchers said a drug called sorafenib may be able to reverse this process."At first, the tumour's growth is halted because the aromatase inhibitor is depriving the cancer of the oestrogen it needs to grow," says...

2008-08-29 09:00:20

Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data from an ongoing Phase I/II clinical trial of ispinesib are scheduled to be presented as a poster presentation at the 2008 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, to be held September 5-7, 2008 at the Hilton Washington in Washington, DC. In June 2008, as part of a poster session at the ASCO Annual Meeting, Cytokinetics announced interim data from the Phase I portion of its ongoing Phase I/II...

2008-08-13 12:00:56

Peregrine Pharmaceuticals has announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer. The new trial is the second Phase II study evaluating bavituximab in advanced breast cancer patients, and Peregrine also is conducting a third Phase II combination therapy trial of bavituximab in non-small cell lung cancer patients. The primary objective...

2008-08-08 09:00:28

The UK's cost-effectiveness watchdog NICE has delivered another blow to the developers of targeted cancer therapies by recommending against the use of four new kidney cancer drugs in the UK. This recommendation suggests that NICE is likely to look unfavorably on a number of other targeted therapies in development, severely limiting future growth of the targeted cancer therapies market in the UK. In its preliminary guidance report on a number of new targeted cancer therapies, the UK's...

2008-08-07 09:01:05

GlaxoSmithKline plans to renegotiate with the UK's Department of Health as part of its attempt to reverse the National Health Service's decision regarding the company's cancer drug Tyverb, reported the Financial Times. According to the news source, GlaxoSmithKline (GSK) is proposing a new 'price-volume' deal to address the concerns of the National Institute for Health and Clinical Excellence (NICE), the government's medicines advisory body, which considers Tyverb as too costly when compared...

2008-08-01 06:00:10

Ariad Pharmaceuticals has initiated a Phase II clinical trial to examine the efficacy and safety of oral deforolimus, its investigational mTOR inhibitor, in patients with advanced breast cancer. In collaboration with Merck & Co, deforolimus is currently being evaluated in multiple clinical trials, both alone and in combination with other therapies, for the treatment of patients with several different cancer types. Under terms of the agreement, Ariad will receive a $15 million...

2008-07-08 12:00:16

The medical advisory panel to the UK National Health Service has recommended that GlaxoSmithKline's Tyverb should not be used on the NHS to treat advanced metastatic breast cancer on the grounds that it is not effective enough to justify its cost. This decision represents not only a blow to GSK but also casts doubt on how many other new cancer therapies will be available in the UK. The UK panel ruled that, based on data showing that the median survival time for women who received Tyverb...

2008-07-08 09:00:12

The National Institute of Health and Clinical Excellence has advised against the use of GlaxoSmithKline's oral cancer drug Tyverb in the UK's National Health Service, reported the Financial Times. According to the Financial Times, The National Institute of Health and Clinical Excellence (NICE) has issued a provisional recommendation that Tyverb for advanced breast cancer failed to meet its threshold for clinical and cost effectiveness. GSK tried to negotiate a 'risk-sharing' arrangement...

2008-06-30 09:01:51

Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the results of a Phase Ib clinical trial designed to evaluate ispinesib in combination with capecitabine, an oral chemotherapy agent commonly used in the treatment of breast cancer. Ispinesib is a novel, small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division. Ispinesib, along with another KSP inhibitor, SB-743921 are chemically-distinct drug candidates that have arisen from a...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related